Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.
The FDA approval of the once-a-month dose is based on a study comparing Actonel 150mg once monthly to Actonel 5mg daily. Similar increases in bone mineral density (BMD) were seen among patients under once-a-month or daily dosing regimens.